PharMerica Reports Results for the Third Quarter of 2012 and Nine Months Ended September 30, 2012

  PharMerica Reports Results for the Third Quarter of 2012 and Nine Months
  Ended September 30, 2012

                  Year to Date Adjusted EBITDA Increases 8%

         Year to Date Adjusted Diluted Earnings Per Share Increase 9%

                Quarterly Generic Dispensing Rate Exceeds 84%

                           Company Updates Guidance

Business Wire

LOUISVILLE, Ky. -- November 01, 2012

PharMerica Corporation (NYSE: PMC), a national provider of institutional
pharmacy and hospital pharmacy management services, today reported its
financial results for the third quarter of 2012 and nine months ended
September 30, 2012.

Commenting on the Company’s results, Gregory S. Weishar, PharMerica
Corporation’s Chief Executive Officer, said, “We are seeing the rewards of
past and ongoing initiatives to improve the customer experience, which is
leading to gains in bed retention rates and early signs of improved sales
productivity. Gross margins have also shown improvement, driven primarily by
brand to generic conversions. This quarter, we dispensed an industry leading
84% generic prescriptions. We are confident we can build upon this momentum
and expect further gains in bed retention rates, sales productivity and margin
improvement over the coming quarters.

“Finally, we expect the fourth quarter will lead to the culmination of a solid
year end. Therefore, we are tightening our 2012 guidance.”

The results for the third quarter and nine months are set forth below:

  *Key Comparisons of Nine Months Ended September 30, 2012 and 2011:

       *Net income for the nine months ended September 30, 2012, was $19.2
         million, or $0.64 diluted earnings per share, compared with $15.5
         million, or $0.53 diluted earnings per share, for the same period in
         2011. Adjusted diluted earnings per share were $0.93 during the first
         nine months of 2012 compared with $0.85 diluted earnings per share in
         the same period in 2011, an increase of 9.4%.
       *Adjusted EBITDA for the nine months ended September 30, 2012, was
         $76.7 million compared with $70.9 million for the same period in
         2011, an increase of 8.2%.
       *Gross profit for the nine months ended September 30, 2012, was $224.3
         million compared with $218.8 million in the same period of 2011.
         Gross margin expanded 220 basis points to 16.0% in the first nine
         months of 2012 compared with 13.8% in the first nine months of 2011.
         The increase in gross margin was a result of the generic dispensing
         rate increasing 330 basis points to 82.8% in the first nine months of
         2012 compared with 79.5% in the first nine months of 2011.
       *Revenues for the nine months ended September 30, 2012, were $1,399.4
         million compared with $1,585.5 million for the same period of 2011, a
         decrease of 11.7%, driven in part by higher generic dispensing.
       *Cash flows provided by operating activities were $103.2 million
         compared with $12.3 million in the same period of 2011.

  *Key Comparisons of Third Quarters Ended September 30, 2012 and 2011:

       *Net income for the third quarter of 2012 was $6.0 million, or $0.20
         diluted earnings per share, compared with $4.8 million, or $0.16
         diluted earnings per share, for the same period in 2011. Adjusted
         diluted earnings per share were $0.33 in 2012 compared with $0.31
         diluted earnings per share in 2011, an increase of 6.5%.
       *Adjusted EBITDA for the third quarter of 2012 was $26.2 million
         compared with $25.4 million in the third quarter of 2011, an increase
         of 3.2%.
       *Gross profit for the third quarter of 2012 was $75.6 million compared
         with $75.7 million in the third quarter of 2011. Gross margin
         expanded 250 basis points to 17.1% in the third quarter of 2012
         compared with 14.6% in the third quarter of 2011. The increase in
         gross margin was a result of the generic dispensing rate increasing
         480 basis points to 84.4% in the third quarter of 2012 compared with
         79.6% in the third quarter of 2011.
       *Revenues for the third quarter of 2012 were $442.0 million compared
         with $518.7 million for the third quarter of 2011, a decrease of
         14.8%, driven in part by higher generic dispensing.
       *Cash flows provided by operating activities for the third quarter of
         2012 were $51.4 million compared with cash flows provided by
         operating activities of $12.0 million in the third quarter of 2011.

Fiscal 2012 Earnings Guidance
The Company updates its fiscal 2012 earnings guidance range as follows:

(in millions, except per share       Previous              Current
data)                                  Guidance                Guidance
Revenues                               $1,815.0 - $1,845.0     $1,825.0 -
                                                               $1,835.0
Adjusted EBITDA                        $93.0 - $102.0          $98.0 - $102.0
Depreciation and amortization          $31.0 - $29.0           $30.5 - $30.3
expense
Interest expense, net                  $9.8 - $9.6             $10.2 - $10.0
Tax rate                               40.3% - 40.1%           40.0%
Net income                             $31.2 - $38.0           $34.4 - $37.0
Adjusted diluted earnings per          $1.05 - $1.28           $1.15 - $1.24
share
Common and common equivalent           29.6                    29.9
shares outstanding
                                                               

As is normal practice, the fiscal 2012 earnings guidance does not consider any
benefits from future acquisitions nor does it consider any merger,
acquisition, integration costs and other charges the Company may incur,
including but not limited to the application of new accounting pronouncements
or other non-recurring charges. Also, the guidance does not consider the
potential impact of any future acquisitions or the expected conversion to
Average Manufacturers Price (“AMP”) because the effect of these items cannot
be reasonably estimated at this time.

Conference Call

Management will hold a conference call to review the financial results for the
third quarter on November2, 2012, at 10:00 a.m. Eastern Time. To access the
live webcast, visit the Investor Relations section of the Company’s website at
www.pharmerica.com or go to www.earnings.com. To access a telephonic replay of
the call, which will be available one hour after the conclusion of the call
through November 16, 2012, please dial 1-888-286-8010 (617-801-6888 if calling
from outside the U.S.) and use passcode 323822112.

About PharMerica

PharMerica Corporation is a leading institutional pharmacy services company
servicing healthcare facilities in the United States. As of September 30,
2012, PharMerica operated 94 institutional pharmacies in 44 states.
PharMerica’s customers are institutional healthcare providers, such as nursing
centers, assisted living facilities, hospitals and other long-term care
providers. The Company also provides pharmacy management services to long-term
care hospitals.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of
Section27A of the Securities Act of 1933, as amended, and Section21E of the
Securities Exchange Act of 1934, as amended, which reflect the Company’s
current estimates, expectations and projections about its future results,
performance, prospects and opportunities. Forward-looking statements include,
among other matters, the information concerning the Company’s “guidance” and
possible future results of operations, the strength of the Company’s financial
performance during 2012, the impact of the brand to generic drug conversions
on the Company, the Company’s ability to identify and consummate future
acquisitions, the Company’s ability to deliver outstanding value to its
shareholders, the Company’s plan to accelerate the rollout of on-site
dispensing technology and cost containment products, the Company’s continued
pursuit of its strategic initiatives including those focused on client
retention and operating margins, and the Company’s ability to renegotiate its
Prime Vendor Agreement by October 2013. Forward-looking statements include
statements that are not historical facts and can be identified by
forward-looking words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “plan,” “may,” “should,” “will,” “would,” “project” and
similar expressions. These forward-looking statements are based upon
information currently available to us and are subject to a number of risks,
uncertainties and other factors that could cause the Company’s actual results,
performance, prospects or opportunities to differ materially from those
expressed in, or implied by, these forward-looking statements. Important
factors that could cause the Company’s actual results to differ materially
from the results referred to in the forward-looking statements we make in this
press release are included in the Risk Factors section set forth in the
Company’s Annual Report on Form 10-K filed with the SEC and in other reports,
including Quarterly Reports on Form 10-Q filed with the SEC by the Company.

You are cautioned not to place undue reliance on any forward-looking
statements, all of which speak only as of the date of this press release.
Except as required by law, we undertake no obligation to publicly update or
release any revisions to these forward-looking statements to reflect any
events or circumstances after the date of this press release or to reflect the
occurrence of unanticipated events. All subsequent written and oral
forward-looking statements attributable to us or any person acting on the
Company’s behalf are expressly qualified in their entirety by the cautionary
statements contained or referred to in this press release and in the Risk
Factors section set forth in the Company’s Annual Report on Form 10-K filed
with the SEC and in other reports filed with the SEC by the Company.


PHARMERICA CORPORATION

UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS

(In millions, except share and per share amounts)

                 Three Months Ended September 30,              Nine Months Ended September 30,
                   2011                  2012                    2011                              2012
                   Amount    % of        Amount    % of        Amount         % of               Amount         % of
                               Revenue                 Revenue                      Revenue                             Revenue
Revenues           $ 518.7     100.0 %     $ 442.0     100.0 %     $ 1,585.5          100.0      %     $ 1,399.4          100.0      %
                                                                                                                        
Cost of goods       443.0     85.4        366.4     82.9        1,366.7         86.2             1,175.1         84.0       
sold
                                                                                                                        
Gross profit         75.7      14.6          75.6      17.1          218.8            13.8               224.3            16.0
                                                                                                                        
Selling,
general and          55.1      10.6          54.0      12.2          162.8            10.3               161.5            11.5
administrative
expenses
                                                                                                                        
Amortization         3.0       0.6           3.2       0.7           8.4              0.5                9.0              0.6
expense
                                                                                                                        
Impairment of
intangible           5.1       1.0           –         –             5.1              0.3                –                –
assets
                                                                                                                        
Merger,
acquisition,
integration         1.8       0.3         6.1       1.4         11.6            0.7              14.3            1.0        
costs and
other charges
                                                                                                                        
Operating            10.7      2.1           12.3      2.8           30.9             2.0                39.5             2.9
income
                                                                                                                        
Interest            2.6       0.5         2.4       0.5         6.3             0.4              7.6             0.6        
expense, net
                                                                                                                        
Income before        8.1       1.6           9.9       2.3           24.6             1.6                31.9             2.3
income taxes
                                                                                                                        
Provision for       3.3       0.6         3.9       0.9         9.1             0.6              12.7            0.9        
income taxes
                                                                                                                        
Net income         $ 4.8       1.0   %     $ 6.0       1.4   %     $ 15.5            1.0        %     $ 19.2            1.4        %
                                                                                                       
                                                                   Three Months Ended                  Nine Months Ended
                                                                   September 30,                       September 30,
                                                                   2011             2012               2011             2012
Earnings per common share:
Basic                                                              $ 0.16           $ 0.20             $ 0.53           $ 0.65
Diluted                                                            $ 0.16           $ 0.20             $ 0.53           $ 0.64
                                                                                                                        
Shares used in computing earnings per common share:
Basic                                                                29,366,998       29,491,234         29,324,094       29,470,473
Diluted                                                              29,531,095       29,846,679         29,423,330       29,829,169
                                                                                                                                     


PHARMERICA CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except share and per share amounts)

                                                (As Adjusted)  
                                                  Dec. 31,          Sept. 30,
                                                  2011              2012
                                                                    
ASSETS
Current assets:
Cash and cash equivalents                         $   17.4          $ 49.5
Accounts receivable, net                              232.2           209.9
Inventory                                             130.6           98.0
Deferred tax assets, net                              36.5            33.1
Prepaids and other assets                            34.5          34.4   
                                                     451.2         424.9  
                                                                    
Equipment and leasehold improvements                  145.0           157.1
Accumulated depreciation                             (92.6  )       (105.5 )
                                                     52.4          51.6   
                                                                    
Deferred tax assets, net                              0.6             0.1
Goodwill                                              214.9           214.9
Intangible assets, net                                100.2           94.0
Other                                                14.7          12.7   
                                                  $   834.0        $ 798.2  
                                                                    
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable                                  $   54.7          $ 43.6
Salaries, wages and other compensation                35.1            33.7
Current portion of long-term debt                     6.3             9.4
Other accrued liabilities                            6.7           15.0   
                                                     102.8         101.7  
                                                                    
Long-term debt                                        293.7           234.4
Other long-term liabilities                           23.7            24.8
                                                                    
Commitments and contingencies
                                                                    
Stockholders’ equity:
Preferred stock, $0.01 par value per share;
1,000,000 shares authorized and no shares             –               –
issued at December 31, 2011, and September
30, 2012
Common stock, $0.01 par value per share;
175,000,000 shares authorized; 30,794,000 and         0.3             0.3
30,940,109 shares issued as of December 31,
2011, and September 30, 2012, respectively
Capital in excess of par value                        355.9           361.4
Retained earnings                                     68.4            87.6
Treasury stock at cost, 1,350,128 shares and
1,455,347 shares at December 31, 2011, and           (10.8  )       (12.0  )
September 30, 2012, respectively
                                                     413.8         437.3  
                                                  $   834.0        $ 798.2  
                                                                             


PHARMERICA CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

                         Three Months Ended       Nine Months Ended
                           September 30,              September 30,
                           2011        2012         2011         2012
Cash flows provided by
(used in) operating
activities:
Net income                 $ 4.8         $ 6.0        $ 15.5         $ 19.2
Adjustments to
reconcile net income
to net cash provided
by (used in) operating
activities:
Depreciation                 4.8           4.6          14.9           13.9
Amortization                 3.0           3.2          8.4            9.0
Impairment charge            5.1           –            5.1            –
Merger, acquisition,
integration costs and        0.5           0.3          1.2            2.2
other charges
Stock-based                  1.3           2.3          4.5            5.2
compensation
Amortization of
deferred financing           0.2           0.3          0.7            0.7
fees
Deferred income taxes        2.9           (2.1 )       9.8            3.9
Loss (gain) on
disposition of               0.1           –            0.3            (0.1  )
equipment
Other                        (0.2  )       0.1          (0.2   )       0.1
Change in operating
assets and
liabilities:
Accounts receivable,         6.1           9.4          (2.2   )       22.3
net
Inventory                    10.8          11.1         (29.1  )       32.7
Prepaids and other           1.9           2.9          (6.9   )       0.1
assets
Accounts payable             (28.3 )       7.2          (21.3  )       (10.8 )
Salaries, wages and          (0.9  )       0.8          11.6           (3.8  )
other compensation
Other accrued               (0.1  )      5.3        –            8.6   
liabilities
Net cash provided by        12.0        51.4       12.3         103.2 
operating activities
                                                                     
Cash flows provided by
(used in) investing
activities:
Purchase of equipment
and leasehold                (3.2  )       (6.6 )       (9.4   )       (13.5 )
improvements
Acquisitions, net of         –             (0.4 )       (8.5   )       (0.8  )
cash acquired
Cash proceeds from the      0.1         –          0.1          0.3   
sale of assets
Net cash used in            (3.1  )      (7.0 )      (17.8  )      (14.0 )
investing activities
                                                                     
Cash flows provided by
(used in) financing
activities:
Repayments of                –             (6.3 )       (240.0 )       (6.3  )
long-term debt
Proceeds from                –             –            250.0          –
long-term debt
Net activity of
long-term revolving          (13.0 )       –            5.4            (50.0 )
credit facility
Payments of debt             –             –            (9.8   )       –
issuance costs
Repayments of capital        (0.3  )       –            (0.7   )       (0.1  )
lease obligations
Issuance of common           0.1           0.4          0.2            0.5
stock
Treasury stock at cost      –           (1.0 )      (0.1   )      (1.2  )
Net cash (used in)
provided by financing       (13.2 )      (6.9 )      5.0          (57.1 )
activities
                                                                     
Change in cash and           (4.3  )       37.5         (0.5   )       32.1
cash equivalents
Cash and cash
equivalents at              14.6        12.0       10.8         17.4  
beginning of period
Cash and cash
equivalents at end of      $ 10.3       $ 49.5      $ 10.3        $ 49.5  
period
                                                                     
Supplemental
information:
Cash paid for interest     $ 2.6        $ 2.2       $ 5.1         $ 7.2   
Cash paid for taxes        $ (0.2  )     $ 1.8       $ 0.1         $ 4.0   
                                                                             


PHARMERICA CORPORATION
SUPPLEMENTAL INFORMATION



MERGER, ACQUISITION, INTEGRATION COSTS AND OTHER CHARGES

The following is a summary of merger, acquisition, integration costs and other
charges incurred by PharMerica for the three and nine months ended September
30, 2011 and 2012 (unaudited).

(In millions,      Three Months Ended              Nine Months Ended
except per       September 30,                 September 30,
share amounts)
                   2011          2012            2011          2012
Merger,
integration
costs and
other charges:
Pre-Pharmacy
transaction        $ (2.0    )     $ –             $ (2.0    )     $ –
litigation
matters
Tender offer         1.1             –               1.1             1.9
costs
Professional
and advisory         0.2             1.2             0.6             2.2
fees
General and          –               –               0.1             –
administrative
Employee costs       –               0.2             0.2             0.2
Severance            –               –               0.2             –
costs
Facility costs       0.3             –               0.2             0.4
Other               0.1           0.8           –             0.9     
                    (0.3    )      2.2           0.4           5.6     
Acquisition
related costs:
Professional
and advisory         0.9             2.8             4.1             5.4
fees
General and          0.1             –               0.7             0.1
administrative
Employee costs       0.5             0.6             2.5             2.1
Severance            0.2             0.2             1.6             0.5
costs
Facility costs       0.3             0.1             1.5             0.5
Other               0.1           0.2           0.8           0.1     
                    2.1           3.9           11.2          8.7     
Total merger,
acquisition,
integration        $ 1.8          $ 6.1          $ 11.6         $ 14.3    
costs and
other charges
Negative
effect on
diluted            $ (0.04   )     $ (0.13   )     $ (0.25   )     $ (0.29   )
earnings per
share


CUSTOMER LICENSED BEDS UNDER CONTRACT AND PRESCRIPTION DATA

The following is a summary of customer licensed beds under contract and
prescription data as of and for the three and nine months ended September 30,
2011 and 2012 (unaudited).


                   Three Months Ended              Nine Months Ended
(In whole          September 30,                   September 30,
numbers,
except where       2011            2012            2011            2012
indicated)
Customer
licensed beds
under
contract:
Beginning of         353,024         326,148         362,901         339,498
period
Additions –
PharMerica           3,229           4,758           13,870          13,758
Corporation
Additions –          905             896             2,295           2,040
Chem Rx
Losses –
PharMerica           (13,561 )       (8,385  )       (30,287 )       (28,681 )
Corporation
Losses – Chem       (1,498  )      (784    )      (6,680  )      (3,982  )
Rx
End of period       342,099       322,633       342,099       322,633 
                                                                   
Prescription
data:
Prescriptions
dispensed (in       10,357        9,711         31,733        29,675  
thousands)
Revenue per
prescription       $ 48.57        $ 43.89        $ 48.49        $ 45.54   
dispensed
Gross profit
per                $ 7.13         $ 7.60         $ 6.71         $ 7.38    
prescription
dispensed



PHARMERICA CORPORATION
SUPPLEMENTAL INFORMATION (Continued)



UNAUDITED RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

(In millions)             Three Months Ended       Nine Months Ended
                            September 30,              September 30,
                            2011        2012         2011        2012
Net income                  $ 4.8         $ 6.0        $ 15.5        $ 19.2
Add:
Interest expense, net         2.6           2.4          6.3           7.6
Merger, acquisition,
integration costs and         1.8           6.1          11.6          14.3
other charges
Provision for income          3.3           3.9          9.1           12.7
taxes
Impairment of                 5.1           –            5.1           –
intangible assets
Depreciation and             7.8         7.8        23.3        22.9  
amortization expense
Adjusted EBITDA             $ 25.4       $ 26.2      $ 70.9       $ 76.7  
Adjusted EBITDA margin       4.9   %      5.9  %      4.5   %      5.5   %


UNAUDITED RECONCILIATION OF DILUTED EARNINGS PER SHARE
TO ADJUSTED DILUTED EARNINGS PER SHARE

(In whole numbers)          Three Months Ended         Nine Months Ended
                            September 30,              September 30,
                            2011          2012         2011          2012
Diluted earnings per        $ 0.16        $ 0.20       $ 0.53        $ 0.64
share
Diluted earnings per
share impact of:
Impairment of                 0.11          –            0.11          –
intangible assets
Merger, acquisition,
integration costs and         0.04          0.13         0.25          0.29
other charges
Tax accounting matters       –           –          (0.04 )      –     
Adjusted diluted            $ 0.31       $ 0.33      $ 0.85       $ 0.93  
earnings per share


UNAUDITED RECONCILIATION OF ADJUSTED EBITDA
TO NET CASH FLOWS FROM OPERATING ACTIVITIES

(In millions)               Three Months Ended         Nine Months Ended
                            September 30,              September 30,
                            2011          2012         2011          2012
Adjusted EBITDA             $ 25.4        $ 26.2       $ 70.9        $ 76.7
Interest expense, net         (2.6  )       (2.4 )       (6.3  )       (7.6  )
Provision for income          (3.3  )       (3.9 )       (9.1  )       (12.7 )
taxes
Merger, acquisition,
integration costs and         (1.3  )       (5.8 )       (10.4 )       (12.1 )
other charges
Provision for bad debt        6.4           7.3          17.6          19.7
Stock-based                   1.3           2.3          4.5           5.2
compensation
Amortization of               0.2           0.3          0.7           0.7
deferred financing fees
Deferred income taxes         2.9           (2.1 )       9.8           3.9
Loss (gain) on
disposition of                0.1           –            0.3           (0.1  )
equipment
Other                         (0.2  )       0.1          (0.2  )       0.1
Changes in assets and        (16.9 )      29.4       (65.5 )      29.4  
liabilities
Net cash flows provided     $ 12.0       $ 51.4      $ 12.3       $ 103.2 
by operating activities
                                                                             


PHARMERICA CORPORATION
SUPPLEMENTAL INFORMATION (Continued)


Use of Non-GAAP Measures

PharMerica calculates Adjusted EBITDA as provided in the reconciliation above
and calculates Adjusted EBITDA Margin by taking Adjusted EBITDA and dividing
it by revenues. PharMerica calculates and uses Adjusted EBITDA as an indicator
of its ability to generate cash from reported operating results. The
measurement is used in concert with net income and cash flows from operations,
which measure actual cash generated in the period. In addition, PharMerica
believes that Adjusted EBITDA and Adjusted EBITDA Margin are supplemental
measurement tools used by analysts and investors to help evaluate overall
operating performance and the ability to incur and service debt and make
capital expenditures. In addition, Adjusted EBITDA, as defined in the Credit
Agreement, is used in conjunction with the Corporation’s debt leverage ratio
and this calculation sets the applicable margin for the quarterly interest
charge. Adjusted EBITDA, as defined in the Credit Agreement, is not the same
calculation as this Adjusted EBITDA table. Adjusted EBITDA does not represent
funds available for PharMerica’s discretionary use and is not intended to
represent or to be used as a substitute for net income or cash flows from
operations data as measured under U.S. generally accepted accounting
principles (“GAAP”). The items excluded from Adjusted EBITDA but included in
the calculation of PharMerica’s reported net income and cash flows from
operations are significant components of the accompanying unaudited condensed
consolidated income statements and cash flows and must be considered in
performing a comprehensive assessment of overall financial performance.
PharMerica’s calculation of Adjusted EBITDA may not be consistent with
calculations of EBITDA used by other companies.

PharMerica calculates and uses adjusted diluted earnings per share, exclusive
of the impact of merger, acquisition, integration costs and other charges, the
impact of the impairment charge and the impact of tax accounting matters, as
an indicator of its core operating results. The measurement is used in concert
with net income and diluted earnings per share, which measure actual earnings
per share generated in the period. PharMerica believes the exclusion of these
charges in expressing adjusted diluted earnings per share provides management
with a useful measure to assess period to period comparability and is useful
to investors in evaluating PharMerica’s operating results from period to
period. Adjusted diluted earnings per share, exclusive of the impact of
merger, acquisition, integration costs and other charges, the impact of the
impairment charge and the impact of tax accounting matters, and the impact of
impairment of intangible assets do not represent the amount that effectively
accrues directly to stockholders (i.e., such costs are a reduction in earnings
and stockholders’ equity) and is not intended to represent or to be used as a
substitute for diluted earnings per share as measured under GAAP. The impact
of merger, acquisition, integration costs and other charges, the impact of the
impairment charge and the impact of tax accounting matters excluded from the
diluted earnings per share are significant components of the accompanying
unaudited condensed consolidated income statements and must be considered in
performing a comprehensive assessment of overall financial performance.

Contact:

PharMerica Corporation
Michael J. Culotta, 502-627-7475
Executive Vice President and Chief Financial Officer
 
Press spacebar to pause and continue. Press esc to stop.